

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2017/191062 A1

(43) International Publication Date
09 November 2017 (09.11.2017)

(51) International Patent Classification:

C07K 16/18 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2017/060266

(22) International Filing Date:

28 April 2017 (28.04.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1607636.6	01 May 2016 (01.05.2016)	GB
1607828.9	04 May 2016 (04.05.2016)	GB

(71) Applicant: UCB BIOPHARMA SPRL [BE/BE]; 60, A1-
lée de la Recherche, 1070 Brussels (BE).

(72) Inventors: ADAMS, Ralph; c/o IPD, UCB Celltech, 208
Bath Road, Slough Berkshire SL1 3WE (GB). HEY-
WOOD, Sam Philip; c/o IPD, UCB Celltech, 208 Bath
Road, Slough Berkshire SL1 3WE (GB).

(74) Agent: UCB INTELLECTUAL PROPERTY; c/o UCB
Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR,
KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

(54) Title: AFFINITY ENGINEERED SERUM PROTEIN CARRIER BINDING DOMAIN

(57) Abstract: The present disclosure relates to a method of modulating the half-life of a binding domain specific to a serum carrier protein by mutating the sequence and a modulated binding domain specific to a serum carrier protein.

WO 2017/191062 A1

AFFINITY ENGINEERED SERUM PROTEIN CARRIER BINDING DOMAIN

The present disclosure relates to a method modulating the half-life of a binding domain specific to a serum carrier protein by mutating the sequence and a modulated binding domain specific to a serum carrier protein.

5

BACKGROUND

Increasing the serum half-life of biological drugs by targeting serum protein carriers, for example human serum albumin (HSA) is now well established^{1,2}. HSA is utilized because it's half-life is 19 days. It is the most abundant protein in blood serum (34-54 g/L), and is 10 widely distributed in tissues.³ Therefore, it is a target that is readily available and safe for binding, particularly as such a small percentage of the total albumin is utilized in this approach.

Of the serum proteins, only IgG has a similarly long half-life (21 days). The long serum half-lives of HSA and IgG are primarily due to protection from intracellular lysosomal 15 degradation by the neonatal Fc receptor (FcRn).^{4,5} FcRn recycles HSA and IgG back to the cell surface following non-specific pinocytosis of plasma into vesicles by endothelial cells and hematopoietic cells lining the vascular space. The pinocytotic vesicles acidify by fusion with the early endosome enabling HSA and IgG to bind to FcRn in a pH dependent manner. Vesicles bearing membrane receptors, including FcRn, and bound HSA and IgG, are recycled 20 back to the cell surface whilst the remaining unbound material is channeled to the lysosome for degradation. HSA and IgG bind weakly to FcRn at neutral pH and so are released back into the circulation when the recycled vesicles are exposed to the neutral pH of the blood.²

HSA can be exploited in one of two ways. One approach is to directly couple the therapeutic protein to HSA, either genetically or chemically.^{6,7} A second approach is to use an albumin 25 binding domain. Examples of binding domains used to date include fatty acids (myristic acid),⁸ organic molecules (Albutag),⁹ synthetic peptides,^{10,11} bacterial albumin binding domains (AlbumodTm),^{12,13} single domain antibodies (NanobodyTm, AlbulAbTm)¹⁴⁻¹⁷ and a Fab.¹⁸

Nguyen *et al* 2006 investigated the half-life of Fab fragments linked to a C-terminal albumin 30 binding peptide. Nguyen concluded that reduced affinity for albumin correlated with a reduced half-life and higher rates of clearance. Figure 3 therein suggests the relationship is almost linear. This paper also went on to say that a very small difference in the fraction of the antibody that is unbound *in vivo* will have a profound effect on the rate of clearance.

The present inventors have investigated the correlation between the affinity of binding 35 domains comprising a VH and VL specific to a serum protein carrier and the *in vivo* half-life of the same. They have established that the duration of the half-life for binding domains is

more complicated than the response for albumin binding peptides, in that large reductions in the observed affinity often translate to a moderate reduction in half-life and in some instances reduced affinity can lead to increases in half-life, which is counter-intuitive.

SUMMARY OF THE DISCLOSURE

5 Thus there is provided a binding domain comprising a VH and VL specific to a serum carrier protein wherein the domain is mutated by a modification in the light chain variable domain (VL), in the heavy chain variable domain (VH) and a combination thereof, and the mutated binding domain has a half-life which is higher or lower than the half-life for the unmutated binding domain, for example with the proviso that the mutation is other than a mutation

10 consisting of I50A, T56A, T95A, V96A, P97A, G98A, Y99A, S100A, T100Aa, Y100Ca, I50A and T95A, I50A and G98A, I50A and Y99A, T56A and T95A, T56A and G98A, and T56A and Y99A of SEQ ID NO: 1.

Thus there is provided a binding domain comprising a VH and VL specific to a serum carrier protein wherein the domain is mutated by a modification selected from one or two amino acids substitutions in the light chain variable domain (VL), one or two mutations in the heavy chain variable domain (VH) and a combination thereof, and the mutated binding domain has a half-life which is higher or lower than the half-life for the unmutated binding domain, for example with the proviso that the mutation is other than a mutation consisting of I50A, T56A, T95A, V96A, P97A, G98A, Y99A, S100A, T100Aa, Y100Ca, I50A and T95A, I50A and G98A, I50A and Y99A, T56A and T95A, T56A and G98A, and T56A and Y99A of SEQ ID NO: 1.

In one embodiment the serum carrier protein is selected from, for example thyroxine-binding protein, transthyretin, α 1-acid glycoprotein, transferrin, fibrinogen and albumin, or a fragment of any thereof, such as albumin, in particular human serum albumin.

25 In one embodiment the binding domain is specific to domain II of albumin.

In one embodiment the mutation is a modification in the VL, for example wherein the mutation is substitution of one or two amino acids in the VL, such as a modification/substitution in a CDR selected from L1, L2, L3 and a combination thereof, in particular wherein the CDR is L1.

30 In one embodiment the mutated amino acid(s) in CDR L1 is/are independently selected from a position 26, 27, 28, 29, 30, 31, 32, 33, 34 and 35, such as position 30.

In one embodiment the amino acid(s) at the relevant position(s) in VL is/are replaced by a hydrophobic residue, for example selected from alanine, isoleucine, phenylalanine, valine, proline, and glycine, such as alanine.

35 In one embodiment the mutations consist of modifications to the VL. Surprisingly the present inventors have established that modifications in the VL can be made which increase

the Kd of the binding domain and reduces the affinity of the binding domain but increases the half-life of the molecule.

In one embodiment the mutation(s) is/are in the VH domain, for example the mutation is substitution of one or two amino acids in the VH, such as mutation in a CDR selected from

5 H1, H2, H3 and combinations thereof, in particular wherein the CDR is H2 and/or H3, more specifically wherein the CDR is H2.

In one embodiment the mutated amino acid(s) in CDR H2 is/are independently selected from a position 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 and combinations thereof, which for example is/are replaced by a hydrophobic residue, in particular

10 independently selected from alanine, isoleucine, phenylalanine, valine, proline, and glycine, such as alanine.

In one embodiment the mutated amino acid(s) is/are in CDR is H3, and in particular the mutated amino acid(s) is/are independently selected from a position 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106 or 107, more specifically the residue 101 is mutated.

15 In one embodiment the amino acid at the relevant position(s) in CDR H3 is replaced by a hydrophobic residue, for example independently selected from alanine, isoleucine, phenylalanine, valine, proline, and glycine, such as alanine.

In one or more embodiments the one or more amino acid substitution(s) is/are a non-conservative amino acid substitution, for example wherein the non-conserved amino acid is selection from the natural amino acids alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, tryptophan, threonine, asparagine, glutamine, glycine, proline, arginine, lysine, aspartic acid and glutamic acid.

In one embodiment the binding domain comprises a CDR grafted variable domain.

20 In one embodiment the binding domain is humanised, for example the binding domain comprises a human framework in the VH and/or VL.

In one embodiment the VH framework is human (for example VH3, such as VH3 1-3 3-23) and comprises 1, 2, 3, 4, 5 or 6 amino acid substitutions, such as amino acids which are donor residues.

25 In one embodiment the VH comprises a sequence selected from SEQ ID NO: 2, 3, 4 and 5 or a variant of any one of the same with at least 95, 96, 97, 98 or 99% similarity or identity, such as a sequence shown in SEQ ID NO: 2, 3, 4, 5 or 6 (particularly 5 or 6).

In one embodiment the VL framework is human (for example Vκ1, such as 2-1- (1) L5), for example comprising 1, 2 or 3 amino acid substitutions, such as amino acids which are donor residues.

In one embodiment the VL domain comprises a sequence selected from SEQ ID NO: 6, 7, 8 and 9 or a variant of any one of the same with at least 95, 96, 97, 98 or 99% similarity or identity.

In one embodiment the VH and VL sequences are selected from the combinations SEQ ID

5 NO: 2 & 6, 2 & 7, 2 & 8, 2 & 9, 3 & 6, 3 & 7, 3 & 8, 3 & 9, 4 & 6, 4 & 7, 4 & 8, 4 & 9, 5 & 6, 5 & 7, 5 & 8 and 5 & 9 or a variant or variants of any of the same with at least 95, 96, 97, 98 or 99% similarity or identity, in particular the VL and VH sequences are SEQ ID NO: 9 and SEQ ID NO: 3, respectively, or the VL and VH sequences are SEQ ID NO: 8 and SEQ ID NO: 4 respectively, or the VL and VH sequences are SEQ ID NO: 9 and SEQ ID NO: 5, 10 respectively, or the VL and VH sequences are SEQ ID NO: 9 and SEQ ID NO: 4.

In one embodiment the binding domain is human.

In one embodiment, the affinity of the binding partners is high, 5nM or stronger, such as 900, 800, 700, 600, 500, 400, 300, 200, 100, 50, or 10pM or stronger.

In one embodiment provided is an antibody molecule comprising a binding domain according 15 to the present disclosure, in particular a multispecific antibody molecule, such as a bispecific.

In one embodiment there is provided a pharmaceutical composition comprising a binding domain according to the present disclosure or an antibody molecule described herein.

In a further aspect there is provided a method of treating a patient comprising administering a 20 therapeutically effect amount of a binding domain according to the present disclosure, an antibody molecule described herein, or a pharmaceutical composition comprising any one of the same.

Also provided is a binding domain according to the present disclosure, an antibody molecule described herein, or a pharmaceutical composition comprising any one of the same, for use in treatment.

25 In one embodiment there is provided a binding domain according to the present disclosure, an antibody molecule described herein or a pharmaceutical composition comprising any one of the same for use in treatment, in particular the treatment of selected from the group consisting of infections (viral, bacterial, fungal and parasitic), endotoxic shock associated with infection, arthritis such as rheumatoid arthritis, asthma such as severe asthma, chronic obstructive 30 pulmonary disease (COPD), pelvic inflammatory disease, Alzheimer's Disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, vasculitis, surgical adhesions, stroke, Type I Diabetes, lyme disease, meningoencephalitis, autoimmune uveitis, immune mediated inflammatory disorders of the central and peripheral nervous system such as 35 multiple sclerosis, lupus (such as systemic lupus erythematosus) and Guillain-Barr syndrome, Atopic dermatitis, autoimmune hepatitis, fibrosing alveolitis, Grave's disease, IgA nephropathy, idiopathic thrombocytopenic purpura, Meniere's disease, pemphigus, primary

biliary cirrhosis, sarcoidosis, scleroderma, Wegener's granulomatosis, other autoimmune disorders, pancreatitis, trauma (surgery), graft-versus-host disease, transplant rejection, heart disease including ischaemic diseases such as myocardial infarction as well as atherosclerosis, intravascular coagulation, bone resorption, osteoporosis, osteoarthritis, periodontitis,

5 hypochlorhydia and cancer, including breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney, and cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof.

10 Use of a binding domain according to the present disclosure, an antibody molecule described herein, or a pharmaceutical composition comprising the same, in the manufacture of a medicament, for example for the treatment of selected from the group consisting of infections (viral, bacterial, fungal and parasitic), endotoxic shock associated with infection, arthritis such as rheumatoid arthritis, asthma such as severe asthma, chronic obstructive pulmonary

15 disease (COPD), pelvic inflammatory disease, Alzheimer's Disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, vasculitis, surgical adhesions, stroke, Type I Diabetes, lyme disease, meningoencephalitis, autoimmune uveitis, immune mediated inflammatory disorders of the central and peripheral nervous system such as multiple

20 sclerosis, lupus (such as systemic lupus erythematosus) and Guillain-Barr syndrome, Atopic dermatitis, autoimmune hepatitis, fibrosing alveolitis, Grave's disease, IgA nephropathy, idiopathic thrombocytopenic purpura, Meniere's disease, pemphigus, primary biliary cirrhosis, sarcoidosis, scleroderma, Wegener's granulomatosis, other autoimmune disorders, pancreatitis, trauma (surgery), graft-versus-host disease, transplant rejection, heart disease

25 including ischaemic diseases such as myocardial infarction as well as atherosclerosis, intravascular coagulation, bone resorption, osteoporosis, osteoarthritis, periodontitis, hypochlorhydia and cancer, including breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney, and cancer, in particular renal cell carcinoma, prostate cancer, liver

30 cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof.

In an independent aspect there is provided a method of selecting a serum protein carrier binding domain to provide a bespoke half-life comprising the steps of: providing a panel of VH/VL pairs specific to said serum protein carrier, and

35 analysing a half-life thereof *in vivo*, and

 selecting a domain which most closely matches the half-life required for a biological molecule comprising the domain in a human subject.

 In one embodiment the serum carrier protein is selected from thyroxine-binding protein, transthyretin, α 1-acid glycoprotein, transferrin, fibrinogen and albumin, or a fragment of any

40 thereof, for example albumin, such as human serum albumin.

In one aspect the panel of VH/VL pairs is prepared by mutating a variable domain in a parent antibody.

In one embodiment the mutation is at least one modification to the VL, for example wherein the VL modification is selected from one or two amino acids substitutions in the light chain

5 variable domain (VL) and the mutated binding domain has a half-life which higher or lower than the half-life for the unmutated binding domain.

In one embodiment the mutation in VL is a mutations in CDR L1, CDRL2, and/or CDRL3, in particular CDR L2 or CDR L3.

In one embodiment the mutation(s) in the binding domain consists of a modification or

10 modifications to the VL domain.

In one embodiment the mutation is at least one modification to the VH.

In one embodiment the mutation is one or two mutations in the heavy chain variable domain (VH), wherein the mutated binding domain has a half-life which higher or lower than the half-life for the unmutated binding domain (also referred to herein as parent antibody).

15 In one embodiment a mutation(s) is in CDR H1, CDRH2, and/or CDRH3, in particular CDR H2 or CDR H3.

In one embodiment the method according to the disclosure further comprises the step of replacing histidine residues in a VH and/or VL (from the panel or for the panel) with an alternative amino acid residue.

20 In one embodiment the method further comprises the step of assessing the properties of one or more binding domains, at two or more biologically relevant pH's, such as about pH 5 and pH7.

In one embodiment the mutations increase the numerical value of the Kd.

In one embodiment there is provided a method wherein the affinity is increased.

25 In one embodiment there is provided a method wherein the affinity is decreased.

In one embodiment a crystal structure of the serum carrier protein with an antibody such as the parent antibody is employed in deciding which residues to modify/mutate.

In one independent aspect there present disclosure provides a method describes in the paragraphs below:

30 1. A method of selecting a serum protein carrier binding domain to provide a bespoke half-life comprising the steps of: providing a panel of VH/VL pairs specific to said serum protein carrier, and
analysing a half-life thereof *in vivo*, and

selecting a domain which most closely matches the half-life required for a biological molecule comprising the domain in a human subject.

2. A method according to paragraph 1, wherein the serum carrier protein is selected from thyroxine-binding protein, transthyretin, α 1-acid glycoprotein, transferrin, fibrinogen and albumin, or a fragment of any thereof.
- 5
3. A method according to paragraph 2, wherein the serum protein carrier is albumin.
- 10 4. A method according to paragraph 3, wherein the albumin is human serum albumin.
5. A method according to any one of paragraphs 1 to 4, wherein the panel of VH/VL pairs is prepared by mutating a variable domain in a parent antibody.
- 15 6. A method according to paragraph 5, wherein the mutation is at least one modification to the VL.
7. A method according to paragraph 6, wherein the VL modification is selected from one or two amino acids substitutions in the light chain variable domain (VL) and the
- 20 20 mutated binding domain has a half-life which higher or lower than the half-life for the unmutated binding domain.
8. A method according to any one of paragraphs 5 to 7, wherein a mutations is in CDR L1, CDRL2, and/or CDRL3, in particular CDR L2 or CDR L3.
- 25 9. A method according to any one of paragraphs 5 to 8, wherein the mutation consists of a modification or modifications to the VL domain.
10. A method according to any one of paragraphss 1 to 8, wherein the mutation is at least one modification to the VH.
- 30 11. A method according to paragraphs 9, wherein the mutation is one or two mutations in the heavy chain variable domain (VH) and a combination thereof, and the mutated binding domain has a half-life which higher or lower than the half-life for the
- 35 35 unmutated binding domain.
12. A method according to paragraphs 10 or 11, wherein a mutation(s) is in CDR H1, CDRH2, and/or CDRH3, in particular CDR H2 or CDR H3.
- 40 13. A method according to any one of paragraphs 1 to 12, which further comprises the step of replace histidine residues in a VH and/or VL employed in the panel with an alternative amino acid residue.

14. A method according to any one of paragraphs 1 to 13, which further comprises the step of assessing the properties of one or more binding domains, at two or more biologically relevant pH's, such as about pH 5 and pH7.
- 5 15. A method according to any one of paragraphs 1 to 14, where the mutation(s) increases the numerical value of the Kd.
16. A method according to any one paragraphs 1 to 15, wherein the affinity increased.
- 10 17. A method according to any one of paragraphs 1 to 15, wherein the affinity in decreased.

DETAILED DISCLOSURE

Surprisingly the present inventors have found that the sequences of the VH and VL can be mutated and the corresponding half-life does not necessarily correspond to the affinity of the binding domain. In particular modifications can be made to the VL where the affinity is maintained or decreased and the half-life is increased.

This allows the half-life to be designed and controlled for molecule to provide a half-life which is relevant to the therapeutic indication. In some embodiments long-half may be desirable. In some embodiments a moderate/medium half-life may be appropriate. In other embodiments a relatively short half-life may be appropriate.

A bespoke half-life as employed herein is a half-life which has been specifically designed for the binding domain by modifying the same.

A “binding domain or site” as employed herein is the part of the antibody that contacts the antigen. In one embodiment the binding domain contains at least one variable domain or a derivative thereof, for example a pair of variable domains or derivatives thereof, such as a cognate pair of variable domains or a derivative thereof.

In one embodiment the binding domain comprises 6 CDRs and a framework and together these elements contribute to the specificity of the binding interaction of the antibody or binding fragment.

30 Variable regions (also referred to herein as variable domains) generally comprise 3 CDRs and a suitable framework.

The term “antibody” as used herein refers to an immunoglobulin molecule capable of specific binding to a target antigen, such as a carbohydrate, polynucleotide, lipid, polypeptide, peptide etc., via at least one antigen recognition site (also referred to as a binding site herein), located 35 in the variable region of the immunoglobulin molecule.

As used herein “antibody molecule” includes antibodies and binding fragments thereof. The term also extends to an antibody format comprising any one of the same.

Parent antibody as employed herein refers to the starting antibody before the mutations to change the half-life are made. The parent antibody may be humanised (which may include 5 incorporate back-mutations containing so-called donor residues) or mutated, for example to remove lysine residues from a CDR or similar. However, modifications present in the parent antibody will not be for the purpose of changing/modifying the half-life. Parent antibody as employed herein includes antibody binding fragments.

“Antibody fragments” as employed herein refer to antibody binding fragments including but 10 not limited to Fab, modified Fab, Fab’, modified Fab’, F(ab’)2, Fv, single domain antibodies, scFv, bi, tri or tetra-valent antibodies, Bis-scFv, diabodies, triabodies, tetrabodies and epitope-binding fragments of any of the above (see for example Holliger and Hudson, 2005, Nature Biotech. 23(9):1126-1136; Adair and Lawson, 2005, Drug Design Reviews - Online 15 2(3), 209-217). The methods for creating and manufacturing these antibody fragments are well known in the art (see for example Verma et al., 1998, Journal of Immunological Methods, 216:165-181). Other antibody fragments for use in the present disclosure include the Fab and Fab’ fragments described in International patent applications WO05/003169, WO05/003170 and WO05/003171. Multi-valent antibodies may comprise multiple 20 specificities e.g. bispecific or may be monospecific (see for example WO92/22853, WO05/113605, WO2009/040562, WO2010/035012, WO2015/197772).

A “binding fragment” as employed herein refers to a fragment capable of binding a target peptide or antigen with sufficient affinity to characterise the fragment as specific for the peptide or antigen.

Specificity (or specific) as employed herein refers where the partners in the interaction only 25 recognise each other or have significantly higher affinity for each other in comparison to non-partners, for example at least 2, 3, 4, 5, 6, 7, 8, 9, 10 times higher affinity, than for example a background level of binding.

Partners as employed herein refer to antigen and antibody binding or ligand and receptor type 30 binding relationships.

At least one modification as employed herein, refers to substitution, addition or deletion of an amino acid, for example to change the properties of the sequence, for example the change 35 hydrophobicity or similar.

The residues in antibody variable domains are conventionally numbered according to a system devised by Kabat *et al.*, 1987. This system is set forth in Kabat *et al.*, 1987, in 35 Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA (hereafter “Kabat *et al. (supra)*”). This numbering system is used in the present specification except where otherwise indicated.

The Kabat residue designations do not always correspond directly with the linear numbering of the amino acid residues. The actual linear amino acid sequence may contain fewer or additional amino acids than in the strict Kabat numbering corresponding to a shortening of, or insertion into, a structural component, whether framework or complementarity determining 5 region (CDR), of the basic variable domain structure. The correct Kabat numbering of residues may be determined for a given antibody by alignment of residues of homology in the sequence of the antibody with a “standard” Kabat numbered sequence.

The CDRs of the heavy chain variable domain are located at residues 31-35 (CDR-H1), residues 50-65 (CDR-H2) and residues 95-102 (CDR-H3) according to the Kabat numbering 10 system. However, according to Chothia (Chothia, C. and Lesk, A.M., *J. Mol. Biol.*, 196, 901-917 (1987)), the loop equivalent to CDR-H1 extends from residue 26 to residue 32. Thus unless indicated otherwise ‘CDR-H1’ as employed herein is intended to refer to residues 26 to 35, as described by a combination of the Kabat numbering system and Chothia’s topological loop definition.

15 The term “Fab fragment” as used herein refers to an antibody fragment comprising a light chain fragment comprising a VL (variable light) domain and a constant domain of a light chain (CL), and a VH (variable heavy) domain and a first constant domain (CH1) of a heavy chain.

20 A Fab’ fragment as employed herein refers to a Fab fragment further comprising a hinge region.

The term “single-chain Fv” or abbreviated as “scFv”, as used herein refers to an antibody 25 fragment that comprises the VH and VL antibody domains linked (for example by a peptide linker) to form a single polypeptide chain. The constant regions of the heavy and light chain are omitted in this format. Single-chain Fv as employed herein includes disulfide stabilised versions thereof wherein in addition to the peptide linker a disulfide bond is present between the variable regions.

Disulfide stabilised scFv may eliminate the propensity of some variable region to dynamically breath, which relates to variable regions separating and coming together again.

30 The term "single domain antibody" as used herein refers to an antibody fragment consisting of a single monomeric variable antibody domain. Examples of single domain antibodies include V_H or V_L or V_HH.

The constant region domains, if present, may be selected having regard to the proposed 35 function of the antibody molecule, and in particular the effector functions which may be required. For example, the constant region domains may be human IgA, IgD, IgE, IgG or IgM domains. In particular, human IgG constant region domains may be used, especially of the IgG1 and IgG3 isotypes when the antibody molecule is intended for therapeutic uses and antibody effector functions are required. Alternatively, IgG2 and IgG4 isotypes may be used

when the antibody molecule is intended for therapeutic purposes and antibody effector functions are not required. It will be appreciated that sequence variants of these constant region domains may also be used. For example IgG4 molecules in which the serine at position 241 has been changed to proline as described in Angal *et al.*, 1993, Molecular Immunology, 1993, 30:105-108 may be used. Accordingly, in the embodiment where the antibody is an IgG4 antibody, the antibody may include the mutation S241P.

In one embodiment the antibody binding fragment does not comprise an Fc region. “Does not comprise an Fc region” as employed herein refers to the lower constant domains, such as CH2, CH3 and CH4 are absent. However, constants domains such as CH1, CKappa/Clambda may be present.

It will also be understood by one skilled in the art that antibodies may undergo a variety of posttranslational modifications. The type and extent of these modifications often depends on the host cell line used to express the antibody as well as the culture conditions. Such modifications may include variations in glycosylation, methionine oxidation, diketopiperazine formation, aspartate isomerization and asparagine deamidation. A frequent modification is the loss of a carboxy-terminal basic residue (such as lysine or arginine) due to the action of carboxypeptidases (as described in Harris, RJ. Journal of Chromatography 705:129-134, 1995). Accordingly, the C-terminal lysine of the antibody heavy chain may be absent.

In one embodiment, the antibody heavy chain comprises a CH1 domain and the antibody light chain comprises a CL domain, either kappa or lambda.

In one embodiment, the antibody heavy chain comprises a CH1 domain, a CH2 domain and a CH3 domain and the antibody light chain comprises a CL domain, either kappa or lambda.

“Multispecific molecule” as employed herein refers to a molecule with the ability to specifically bind at least two distinct antigens, for example different antigens. In one embodiment the multispecific molecule is a bispecific, trispecific or tetraspecific molecule, in particular a bispecific molecule.

Examples of suitable multispecific molecules are known in the art.

In one embodiment multispecific formats include those known in the art and those described herein, such as wherein the molecule format is selected from the group comprising or consisting of: diabody, scdiabody, triabody, tribody, tetrabodies, tandem scFv, FabFv, Fab’Fv, FabdsFv, Fab-scFv, diFab, diFab’, tandem scFv-Fc, scFv-Fc-scFv, scdiabody-Fc, scdiabody-CH3, Ig-scFv, scFv-Ig, V-Ig, Ig-V, Duobody and DVDIg, which are discussed in more detail below.

Molecule as employed herein is used in the biochemistry sense to refer to a group of atoms that form an organic, in particular proteinaceous mass, which includes a complex suitable for handling as a single entity under appropriate conditions once the complex has been formed.

5 Molecule and construct are used interchangeably herein, unless the context indicates otherwise. Although, construct may be employed more often to refer to a polynucleotide molecule and molecule may be employed more often to refer an entity primarily comprising an amino acid sequence.

10 Antigens of interest, which may be targeted by an binding domain in the antibody molecule of the present disclosure, may also be any medically relevant protein such as those proteins upregulated during disease or infection, for example receptors and/or their corresponding ligands. Particular examples of cell surface proteins include: adhesion molecules, integrins such as β 1 integrins (e.g. VLA-4), E-selectin, P selectin or L-selectin, CD2, CD3, CD4, CD5, CD7, CD8, CD11a, CD11b, CD18, CD19, CD20, CD23, CD25, CD33, CD38, CD40, CDW52, CD69, CD134 (OX40), ICOS, BCMP7, CD137, CD27L, CDCP1, DPCR1, DPCR1, dudulin2, FLJ20584, FLJ40787, HEK2, KIAA0634, KIAA0659, KIAA1246, KIAA1455, LTBP2, LTK, MAL2, MRP2, nectin-like2, NKCC1, PTK7, RAIG1, TCAM1, SC6, BCMP101, BCMP84, BCMP11, DTD, carcinoembryonic antigen (CEA), human milk fat 20 globulin (HMFG1 and 2), MHC Class I and MHC Class II antigens, and VEGF, and where appropriate, receptors thereof.

Soluble antigens include interleukins such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-16 or IL-17, IL-21, IL-23, viral antigens for example respiratory syncytial virus or cytomegalovirus antigens, immunoglobulins, such as IgE, interferons such 25 as interferon α , interferon β or interferon γ , tumour necrosis factor- α , tumor necrosis factor- β , colony stimulating factors such as G-CSF or GM-CSF, and platelet derived growth factors such as PDGF- α , and PDGF- β and where appropriate receptors thereof. Other antigens include bacterial cell surface antigens, bacterial toxins, viruses such as influenza, EBV, HepA, B and C, bioterrorism agents, radionuclides and heavy metals, and snake and spider 30 venoms and toxins.

In the context of this specification "comprising" is to be interpreted as "including".

Aspects of the invention comprising certain elements are also intended to extend to alternative embodiments "consisting" or "consisting essentially" of the relevant elements.

Embodiments and descriptions of the disclosure may and will be combined where technically 35 appropriate.

Any positive embodiment or combination thereof described herein may be the basis of a negative exclusion i.e. a disclaimer.

EXAMPLES

Figure 1. Humanization and affinity reduction of antibody CA645. The heavy and light chain sequences of antibody CA645 are aligned with human germline acceptor framework sequences VH3 1-3 3-23/JH4 and V κ 1 2-1-(1) L5/J κ 4. Rabbit residues are in red, human residues are in black and CDRs are in blue (J-region CDR residues are shown but acceptor V-region CDRs are not). The grafted VH (gH) and VL (gL) sequences are shown below their corresponding human acceptor germline frameworks. Framework sequence differences between the rabbit and human framework sequences are shown with asterisks. Rabbit framework residues retained in the humanized grafts are highlighted in bold.

Figure 2. Binding of FcRn to HSA and MSA in the presence or absence of CA645 gL4gH5 Fab. Binding to HSA in absence of Fab (red circle), binding to HSA in presence of Fab (red triangle), binding to MSA in absence of Fab (blue square), binding to MSA in presence of Fab (blue triangle).

Figure 3. (A) Crystal structure of CA645 gL4gH5 Fab in complex with HSA (B) Superimposition of CA645 Fab-HSA with the crystal structure of FcRn-HSA complex, PDB code 4N0F. FcRn is composed of heavy chain, shown in green, and common β 2-microglobulin (β 2M), shown in orange (C) Superimposition of CA645 Fab-HSA with the crystal structures of HSA in complex with myristic acid, PDB code 1BJ5, shown in red, ibuprofen, PDB code 2BXG, shown in blue, and warfarin, PDB code 2BXD, shown in magenta. The seven fatty acid (FA) binding sites in albumin are also labelled.

Figure 4. Superimposition of CA645-HSA with RbSA. Close up views of regions around albumin residues at positions (A) 364, (B) 320 and (C) 358. CA645 heavy chain shown in blue; CA645 light chain shown in silver; HSA shown in wheat; RbSA shown in pink. Clashes are defined as two heavy atoms from different residues being within 2 \AA of each other and are denoted by a black circle.

Figure 5. Pharmacokinetics. CA645 Fab grafts were intravenously injected into mice at 10mg/kg and serum concentrations of the Fabs were determined at various time points by ELISA. Data were normalized considering maximal concentration at the first time point.

Figure 6. Percentage of free CA645 Fab in blood versus affinity for MSA. % free Fab calculated for K_D range of 1 - 10^6 nM (blue diamonds) using solution of mass

action quadratic equation.⁴⁵ % free Fab for grafts gL4gH5, gL5gH5, gL4gH37 and gL5gH47 with affinities for MSA of 2.2, 316, 1146 and 62400 nM, respectively, are shown as red squares.

Figure 7. Sequences of the disclosure

5 Table 1. Activity profiles of anti-human serum albumin (HSA) antibodies. Fluorescent microvolume assay technology (FMAT) screening of secreted anti-HSA antibodies in B cell supernatants for binding to 100ng/ml HSA in the presence or absence of 25 μ M albumin binding compounds (warfarin, ibuprofen, myristic acid, and copper chloride) and for binding to 100ng/ml rat serum albumin (RSA). FL = fluorescence intensity. Equilibrium binding constants (K_D) of anti-HSA rabbit Fab fragments for human and mouse serum albumin (MSA), and of equivalent humanized IgG antibodies for HSA, MSA and RSA determined by surface plasmon resonance (SPR).

10 Table 2. Affinity of CA645 gL4gH5 Fab for serum albumin from different species.

15 Association (k_a) and dissociation (k_d) rate constants and equilibrium binding constants (K_D) determined by SPR.

Table 3. X-ray data collection and refinement statistics. Values in parentheses are for highest-resolution shell.

20 Table 4. Binding kinetics and pharmacokinetics of CA645 Fab grafts. Association (k_a) and dissociation (k_d) rate constants and equilibrium binding constants (K_D) determined by SPR. 3 mice (M1-3)/group were dosed intravenously at 10 mg/kg with each CA645 graft. Mean and standard deviation (SD) of each group is shown. *measured by steady state.

Table 5 Shows affinity for various grafts.

25 Table 6. Affinity of CA645 gL4gH5 Fab for HSA over pH range 5.0-7.0

Table 7. (A) (B) (C) Binding kinetics of CA645 Fab grafts. Association (k_a) and dissociation (k_d) rate constants and equilibrium binding constants (K_D) determined by SPR.

Antibody discovery

30 Two Half Lop rabbits were immunised subcutaneously with 200 μ g HSA (Jackson ImmunoResearch). Complete Freund's adjuvant (Sigma Aldrich) was co-administered with the first dose and subsequent doses included incomplete Freund's adjuvant. B cells were harvested from the rabbit sera and cultured for 7 days to induce clonal expansion and antibody secretion. Fluorescence microvolume assay technology (FMAT) was used to screen the supernatants for binding to HSA.²⁰⁻²² The supernatants were mixed with streptavidin beads (Bangs Laboratories, Inc) coated with biotinylated goat anti-rabbit Fc and Alexa Fluor

647 Chrompure Human Albumin (Jackson ImmunoResearch). Plates were read on an Applied Biosystems 8200 Cellular Detection System. The 48 wells with the highest fluorescence intensity (FL) signal were transferred to a single master plate and the screening repeated as before but with two additional screens. In one screen, Alexa Fluor 647

5 Chrompure Human Albumin was pre-incubated for 1 hour with a 25 μ M solution of albumin binders; warfarin, ibuprofen, myristic acid, and copper chloride (all individually sourced from Sigma Aldrich). In the second screen, HSA was replaced with rat serum albumin (Sigma Aldrich) that had been labelled using Alexa Fluor 647 \circledR monoclonal antibody labelling kit (Molecular Probes).

10

Individual HSA specific B-cells were isolated by fluorescent foci method.²⁰⁻²² B cells from positive wells were mixed with streptavidin beads (Bangs Laboratories, Inc) coated with biotinylated-HSA (Jackson ImmunoResearch) and goat anti-rabbit Fc fragment fluorescein isothiocyanate conjugate (Chemicon). Following 1 hour incubation at 37°C, antigen-specific B 15 cells could be identified due to the presence of a fluorescent halo surrounding that B cell. An Olympus IX70 microscope and an Eppendorf micromanipulator were used to identify and transfer the individual B cells to PCR tubes. The heavy and light chain immunoglobulin variable (V) region genes of single cells were amplified by RT-PCR and cloned into UCB mammalian expression vectors containing rabbit heavy C_H1 and rabbit light C_K regions, 20 respectively. Following transient expression in HEK293 cells, anti-HSA recombinant Fabs were further screened in SPR binding assays against HSA and MSA.

Humanization

Albumin specific antibodies were humanized *in silico* by grafting the CDRs from antibody 25 V-regions onto the V_K1 and V_H3 human germline antibody V-region frameworks. The CDR's grafted from the donor to the acceptor sequence were as defined by Kabat *et al.*,³² with the exception of CDR-H1 (residues 26-35) where the combined definitions of Kabat *et al.*, and loop structure was used.²³ Where a framework residue differed between the donor rabbit sequence and the acceptor human sequence in a position that was considered to be 30 important for retention of antigen binding, then the donor residue was included in the initial conservative graft.²¹ The conservative graft genes were chemically synthesized by Entelechon, GmbH. Heavy chain graft genes (gH1) were cloned into two UCB expression vectors, one containing human γ 1 C_H1 domain and another containing the full human γ 1 constant region. Light chain graft genes (gL1) were cloned into a UCB expression containing 35 human kappa constant region (Km3 allotype). These constructs were subsequently modified by oligonucleotide-directed mutagenesis to create a number of different variants of both the heavy and light chain grafts. Heavy and light chain vectors were co-transfected into HEK293

cells and the recombinant Fab or IgG molecules screened using a SPR binding assay to measure affinity for HSA, MSA, RSA, CSA, RbSA and BSA.

Antibody expression

Antibodies were transiently expressed in either HEK-293 cells using 293Fectin lipid transfection (Life Technologies, catalog #12347-019, according to the manufacturer's instructions) or CHO-S XE cells, a CHO-K1 derived cell line,³³ using electroporation. HEK-293 cells were used for small scale expression (< 100 ml) to prepare antibodies for SPR analysis. CHO-S XE cells were used for large scale expression (1 litre) to prepare antibodies for crystallography and *in vivo* pharmacokinetic studies.

10

Protein purification

Affinity chromatography was used to purify Fab protein from culture supernatants.

Supernatants were passed over a HiTrap Protein G column (GE Healthcare) at a flow rate that gave a column contact time of 25 min. Following a washing step with PBS pH 7.4, the bound material was eluted with 0.1 M glycine pH 2.7 and neutralized with 2 M Tris-HCl (pH 8.5). Fractions containing Fab were pooled, quantified by absorbance at 280 nm, and concentrated using Amicon Ultra centrifugal filters (Merck Millipore). To isolate the monomeric fraction, size exclusion chromatography over a HiLoad 16/60, Superdex 200 column (GE Healthcare) equilibrated with PBS, pH 7.4, was used. Fractions containing monomeric Fab were pooled, quantified, concentrated and stored at 4 °C.

Surface Plasmon Resonance

The binding affinities and kinetic parameters for the interactions of antibodies were determined by surface plasmon resonance (SPR) conducted on either a Biacore T200 or 25 Biacore 3000 using CM5 sensor chips (GE Healthcare Bio-Sciences AB) and HBS-EP (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% v/v P20, pH7.4) running buffer. For analysis at pH 7.0, 6.0, 5.5 and 5.0, a running buffer of 40mM citric acid, 80mM sodium phosphate 50mM NaCl, 3mM EDTA, 0.05% v/v P20 was used. The required pH was achieved by altering the ratio of citric acid to sodium phosphate. All experiments were 30 performed at 25 °C. The antibody samples were captured to the sensor chip surface using either a human F(ab')₂-specific or human Fc-specific goat Fab (Jackson ImmunoResearch). Covalent immobilisation of the capture antibody was achieved by standard amine coupling chemistry to a level of 6000-7000 response units (RU).

35 Human (Jackson ImmunoResearch, catalog #009-000-051), mouse (Sigma Aldrich, catalog #A3559), rat (Sigma Aldrich, catalog #A6414), rabbit (Sigma Aldrich, catalog #A0764), bovine (Sigma Aldrich, catalog #05470) and cynomolgus (Equitech-Bio, #CMSA-0050) albumin were titrated over the captured antibody at various concentrations from 50 nM to 500

μM. Each assay cycle consisted of firstly capturing the antibody sample using a 1 min injection, before an association phase consisting of a 3 min injection of albumin, after which dissociation was monitored. After each cycle, the capture surface was regenerated with two 1 min injections of 40 mM HCl followed by 30 s of 5 mM NaOH. The flow rates used were 10 5 μl/min for capture, 30 μl/min for both the association and dissociation phases, and 10 μl/min for regeneration. A blank flow-cell was used for reference subtraction and buffer-blank injections were included to subtract instrument noise and drift. Kinetic parameters were determined by simultaneous global-fitting of the resulting sensorgrams to a standard 1:1 binding model using Biacore T200 Evaluation software v2.0.1 and BIAEvaluation software 10 v4.1.1, with the exception of CA645 gL5gH47 which was fitted in prism using steady state affinity model.

To measure the effect of CA645 Fab on the binding potency of FcRn to albumin by SPR, a Biacore3000 instrument was used with a CM5 chip prepared by immobilisation of HSA and 15 MSA on separate flow cells to levels of 270 RU and 247 RU respectively. FcRn samples were prepared over the range 50 nM to 50 μM in running buffer, (100 mM MES, 150 mM NaCl, 0.05% v/v P20, pH 5.5) and they also contained either zero or 100nM CA645 Fab. Each assay cycle was run at a flow rate of 10 μl / min and consisted of either a 5 min 20 injection of 100 nM CA645 Fab to pre-saturate immobilised albumin, followed by a 5 min injection of one of the above FcRn solutions prepared in the presence of CA645 Fab, or a 5 min injection of running buffer followed by a 5 min injection of one of the above FcRn 25 solutions in the absence of CA645 Fab. In either case a third 5 min injection followed immediately at the end of the second injection, using the ‘coinject’ mode, comprising respectively, buffer or 100 nM CA645 Fab. A blank flow-cell was used for reference subtraction and blank cycles, where FcRn was replaced with buffer, were included to subtract 30 drift and noise. Cycle regeneration was as above. Blank corrected plateau binding levels of FcRn were plotted in Prism and fitted to a steady state model.

Binding kinetics of wild type and mutant CA645 Fabs at pH 5.5 were also investigated in 30 reverse format on the Biacore3000 using the immobilised albumin chip. In this case cycles were run where Fab solutions over the range 5 to 5000 nM were injected with 5 min association and dissociation phases. Buffer blank cycles were also included to correct for drift.

35 **Crystallography**

To prepare the complex, purified CA645 Fab and fatty acid-free HSA (Sigma Aldrich, catalog #A3782) were mixed in a molar ratio of 1:1 and incubated overnight at 4 °C. Both CA645 Fab and the complex were purified by size exclusion chromatography over a HiLoad

16/60, Superdex 200 column (GE Healthcare) equilibrated with 50 mM NaCl, 25 mM Tris, 5% (v/v) glycerol. Fractions containing either CA645 Fab or the complex were pooled and concentrated to 10 mg/ml and 70 mg/ml, respectively. Conditions suitable for crystal growth were identified by the sitting drop vapour diffusion method using commercially available 5 crystallization screens (Qiagen).

To generate diffraction quality crystals, hanging drop vapour diffusion method was used where 1 μ l of protein solution was mixed with 1 μ l of reservoir solution. For CA645 Fab, the reservoir contained 500 μ l 2 M DL-Malic acid. Crystals were harvested and flash frozen in 10 liquid nitrogen without additional cryoprotectant. Diffraction data to 2.68 \AA was collected from a single crystal on the I04 beamline at Diamond Light Source, Oxford, UK and processed using MOSFLM and SCALA.³⁴⁻³⁶ The structure of CA645 Fab was solved by molecular replacement with Phaser,³⁷ using coordinates of an in-house Fab structure as a search model. For the complex, the reservoir contained 500 μ l 0.1 M Citric acid pH 4.4, 0.1 15 M di-Sodium hydrogen phosphate, 38% v/v Ethanol and 5% v/v Polyethylene glycol 1000 (PEG1000). The crystals were cryoprotected by multiple additions to the drop of 1 μ l reservoir buffer containing 25% (v/v) PEG1000, until the concentration of PEG1000 in the drop reached 20%. To minimise crystal stress, each addition was spaced at least 1 hour apart. Crystals were harvested and flash frozen in liquid nitrogen. Diffraction data to 3.58 \AA was 20 collected from a single crystal on the I02 beamline at Diamond Light Source, Oxford, UK and processed using XDS.³⁸ The structure of the complex was solved by molecular replacement with Phaser using coordinates of CA645 Fab structure and HSA (PDB code 4G03)³⁹ as search models.

25 Both initial structures were refined with iterative cycles of simulated annealing, energy minimisation and manual rebuilding using CNS^{40,41} and COOT.⁴² Due to the rather low resolution of the complex, the model was constrained during refinement by using the DEN function of CNS. Model geometry was validated using Molprobity.⁴³ Molecular visualisations were generated with Pymol.⁴⁴ Data collection and refinement statistics are 30 summarised in Table 3.

Accession codes

Coordinates and structure factors of CA645 Fab and the CA645 Fab-HSA complex have been deposited in the Protein Data Bank (PDB) with accession codes, X and Y, respectively.

35

Mouse pharmacokinetics

Three male BALB/c mice were dosed intravenously at 10 mg/kg with the antibody. Serial blood samples were collected from the tail venipuncture at several time points up to 100 hr

post dose. To obtain sera, blood samples were centrifuged for 5 min at 10,000 rpm at room temperature and analysed for the antibody concentration by ELISA. An antibody against the Fab antigen and an anti-human kappa chain-Horseradish peroxidase conjugate (Stratech) was used as the capture and secondary antibody, respectively. A purified sample of the Fab antigen was used as the standard. Plates were developed using TMB peroxidase solution (Sigma-Aldrich) and read at 450 nm (reference at 630 nm). Pharmacokinetic parameters were calculated from the final dataset using Phoenix WinNonlin 6.2 software.

Calculation of free CA645 Fab

To determine the concentration of unbound Fab (molecular weight = 47907 Da), in 2 ml of blood, of a 20 g mouse, following a dose at 10 mg/kg the following equation was used:³¹
 Free Fab concentration $x = (-b + \sqrt{b^2 - 4ac})/2a$

Where:

$$\begin{aligned}
 b &= (-K_A \cdot [Tab]) + 1 + (K_A \cdot [Tag]) \\
 15 \quad a &= K_A = 1/K_D \\
 c &= (-[Tab]) \\
 K_D &= \text{affinity of Fab} \\
 K_A &= \text{equilibrium constant of association} \\
 [Tab] &= \text{concentration of Fab (2087 nM)} \\
 20 \quad [Tag] &= \text{concentration of albumin (600 } \mu\text{M)}
 \end{aligned}$$

To calculate percentage of free Fab % Free Fab = ([free Fab]/[Tab])*100

Results

Generation and characterization of a mAb to serum albumin across species

To generate a panel of anti-HSA antibodies with cross species reactivity, two rabbits were immunized with HSA. B cells were harvested from the sera, cultured, stimulated to secrete IgG and screened using fluorescent microvolume assay technology (FMAT) to identify antigen-specific wells.²⁰⁻²² Further FMAT screens assessed binding to RSA and binding to HSA in the presence or absence of known albumin binding compounds; warfarin, ibuprofen, myristic acid, and copper chloride. Data for the five top-ranked antibodies is shown in **Table 1**. The fluorescence intensity signal for binding to HSA was lowest for CA645. However, CA645 did retain 80% of binding activity in the presence of the compounds whereas CA646, CA647, CA648 and CA649 retained only 40%. The levels of binding to HSA and RSA were most closely matched for CA645 and CA646, being within 5-fold. In contrast, the levels of binding to RSA by CA647, CA648 and CA649 were 9 to 18-fold lower than for HSA.

35

To recover the heavy and light chain variable regions of the five antibodies, fluorescent foci method was used to isolate single B cells and then RT-PCR was performed. The variable regions were cloned into expression vectors containing rabbit heavy C_H1 and light chain

constant regions and then the DNA sequenced. This revealed that the antibody sequences were unique with the exception of CA645 and CA646 which had identical heavy chain sequences. Given CA645 and CA646 must bind to the same epitope through the heavy chain it is unclear why CA646 binding was more affected by the presence of ligands. Also

5 determined from the sequencing was that the complementarity determining regions (CDRs) of all of the antibodies lacked histidine residues. This was important for further progression of these antibodies since histidine residues protonate at acidic pH and this can potentially disrupt antigen binding.

10 Following transfection of HEK293 cells, the recombinant Fab molecules were analysed by surface plasmon resonance (SPR) for affinity for HSA and mouse serum albumin (MSA). CA645 and CA646 both exhibited the strongest affinities for HSA, at 0.31 nM and 0.14 nM, respectively, and for MSA at 2.6 nM and 1.6 nM, respectively (**Table 1**). Furthermore, their affinities for HSA and MSA were the most closely matched of all of the antibodies. This was 15 in line with the B cell supernatant screening data against HSA and RSA.

Humanization and selection of lead candidate

All five antibodies were humanized by grafting the CDRs onto human V κ 1 and VH3 frameworks and back-mutating framework residues in positions considered important for 20 retention of binding activity.²³ The humanization scheme for CA645 is shown in **Figure 1**. Of note is that the framework three regions (residues 66-94) of the rabbit donor heavy chains were shorter than that of the human acceptor framework sequences. CA647 and CA649 were shorter by one residue whereas CA645 and CA646 (identical sequences) and CA648 were shorter by two residues. In all cases, the gap was retained in the initial conservative gL1gH1 25 graft.

The conservative grafts were expressed as human IgG1 antibodies and analysed by SPR for binding to HSA, MSA and RSA. The humanized IgGs displayed the same trend in binding to HSA and MSA as observed with the recombinant parental rabbit Fabs (**Table 1**). The 30 affinities for HSA of CA647, CA648 and CA649 were similar to those of CA645 and CA646 but they showed a 6- to 10-fold reduction in affinity for MSA by comparison. The affinities for RSA of CA648 and CA649 also showed a 5- to 10-fold reduction in comparison with CA645 and CA646. CA646 exhibited marginally stronger affinities for HSA, MSA and RSA than CA645 but the transient expression yields were 4-fold lower at 35 mg/ml compared with 35 161 mg/ml (**Table 1**). Based on the near maximal retention of binding to HSA in the presence of known albumin binders, the consistent binding activity for albumin across multiple species and good yields in transient expression, CA645 was selected as our lead candidate for further progression. Further graft variants of CA645 gL1gH1 were generated by replacing rabbit

donor residues with human acceptor residues and filling the gap in framework three of the heavy chain with the equivalent human residues. The graft variants were assessed on affinity for HSA and transient yield expression (data not shown). The final graft pairing selected was gL4 and gH5 (**Fig.1**).

5

The affinities of CA645 gL4gH5 Fab for HSA, MSA, RSA and rabbit serum albumin (RbSA) were shown to be 4.6, 7.1, 54 and 162 nM, respectively (**Table 2**). Significantly for utility of CA645 gL4gH5 Fab in cynomolgus monkey toxicology studies and disease models, the affinity for cynomolgus serum albumin (CSA) was very similar to that of HSA at 3.3 nM. In 10 addition, CA645 Fab failed to bind to bovine serum albumin.

To determine whether CA645 gL4gH5 Fab is likely to remain bound to albumin in the acidic environment of the early endosome and be recycled to the cell surface, the affinity was measured at pH 5.0-7.0 (**Table S1**). The affinities of CA645 gL4gH5 Fab for HSA at pH 5.0, 15 pH 5.5, pH 6.0, and pH 7.0 were 7.1, 10.7, 12.5 and 13.3 nM indicating that binding is largely unaffected within this physiologically relevant pH range.

To determine whether HSA can bind to FcRn in the presence of CA645 gL4gH5 Fab, SPR was used. The kinetic assays were conducted at pH5.5 to ensure optimal binding by FcRn to 20 albumin. HSA or MSA was bound directly onto the sensor chip, then either CA645 gL4gH5 Fab, to saturate CA645 albumin binding sites, or running buffer was injected into the flow cell. This was followed by an injection of FcRn plus CA645 Fab, or FcRn alone. CA645 Fab was included in the co-injection with FcRn to maintain CA645 binding site saturation. **Figure 2** shows the levels of FcRn binding to both HSA and MSA following subtraction of the 25 signals for CA645. Binding by FcRn to both albumins was unaffected by the presence of CA645 gL4gH5 Fab.

Crystallography

To identify where CA645 binds to HSA, the crystal structure of CA645 Fab-HSA complex 30 was determined. The CA645 Fab-HSA complex protein preparation was concentrated to 70mg/ml,²⁴ and crystallized using ethanol and PEG1000 as precipitants. To aid solving the structure of the complex with molecular replacement, we also determined the structure of unbound CA645 Fab. We observed single copies of both the Fab and Fab-HSA complex in the asymmetric units of their respective crystals (**Table 3**). The structure of free Fab was 35 refined to 2.68 Å with a final R_{work} value of 21.14% and R_{free} value of 25.13%. The structure of the complex was refined to 3.6 Å with a final R_{work} value of 21.38% and R_{free} value of 25.23%.

The crystal structure of the CA645 Fab-HSA complex showed that CA645 binds to domain II of HSA (**Fig.3A**). Superimposition of the crystal structure of FcRn in complex with HSA (PDB code 4N0F),²⁵ showed that CA645 does not block binding of HSA to FcRn (**Fig.3B**). HSA contains seven fatty acid (FA) binding sites. Sites FA7 and FA3/FA4 are the two main 5 drug binding sites.²⁶ Drugs also bind at sites FA1, FA5 and FA6 but with weaker affinity. Metal ion binding sites are located between domains I and II and at a site at the N-terminus.²⁷ Superimposition of the complex with the crystal structures of HSA in complex with warfarin (PDB code 2BXD),²⁸ ibuprofen (PDB code 2BXG)²⁸ and myristic acid (PDB code 1BJ5)²⁹ showed that CA645 binds close to site FA6 and does not occlude the main drug (FA7 and 10 FA3/FA4), fatty acid or metal ion binding sites (**Fig.3C**).

The binding kinetics of CA645 gL4gH5 Fab to HSA in comparison with those for MSA, CSA, RSA and RbSA (**Table.2**) may be explained by close visual inspection of the crystal structure. The epitope on HSA is formed by residues F206, G207, R209, C316, K317, 15 AEAKD 320-324, K351, E354, E358, K359, C361, A362 and A364. The affinities of CA645 for CSA (3.3 nM) and MSA (7.1 nM) are very similar to the affinity for HSA (4.6 nM). This is likely due to the presence in CSA and MSA of the same residues that form the epitope in HSA. RSA shares all of these residues except for position 364 which is glycine. Position 364 is located at the tip of a short loop (positions 362-365) that links two α -helices (positions 366- 20 398 and 342-361) together (**Fig.4A**). This short loop is bound by CDR's 1 and 2 of the CA645 heavy chain. The affinity of CA645 for RSA is approximately 10-fold lower than for HSA. It is possible that the absence of the alanine side chain increases the flexibility of the loop, compared with that of HSA, and alters the binding kinetics.

25 RbSA shares all of the HSA epitope residues except positions 320, 358 and 364. Superimposition of the crystal structure of RbSA (PDB code 3V09)³⁰ showed clear clashes with CA645 Fab at positions 320 and 358, and a potential clash at position 364. In RbSA, position 364 is aspartic acid and whilst there was no clear clash, this position is a contact residue and therefore likely to influence binding by CA645. In HSA, position 320 is alanine 30 and it forms a hydrophobic interaction with F58 of CDRH2 (**Fig.4B**). In RbSA, position 320 is glutamic acid and it clashes with CDRH2 residues W52 and F58. Residue E358 in HSA forms a hydrogen bond network with S100 and T100a of CDRH3 (**Fig.4C**). Position 358 in RbSA is lysine and it clashes with Y99 of CDRH3. The weaker affinity of CA645 for RbSA compared with HSA is entirely due to an 18-fold reduction in the association rate (**Table.2**). 35 This is likely to be caused by the presence in RbSA of the larger side chains at positions 320 and 358, and possibly 364.

Pharmacokinetics of reduced affinity variants

To investigate the correlation between the half-life of CA645 and its affinity for albumin, we generated a panel of mutants of CA645 gL4gH5 Fab with a broad range of reduced affinities and then analysed their pharmacokinetic properties in mice. The mutations were designed using the crystal structure of the CA645 gL4gH5 Fab-HSA complex as a guide.

5 Oligonucleotide-directed mutagenesis was used to generate twenty variants across six residue positions of the heavy chain and twenty seven variants across six residue positions of the light chain (**Tables 4, S2A, S2B and S2C**). BALB/c mice were dosed by a single intravenous injection at 10 mg/kg with CA645 gL4gH5 Fab and a subset of four of the Fab variants, gL5gH5, gL4gH37, gL5gH37 and gL5gH47. Blood sera were sampled over 103 hours and
10 the level of Fab quantified by ELISA.

CA645 gL5gH37 showed no detectable binding to HSA by SPR and was cleared rapidly with a serum half-life of only 0.48 ± 0.06 h (**Table 4**). This is in line with the short half-life (0.7 h) of an anti-TNF Fab observed in rats.¹⁹ In contrast gL4gH5 exhibited a significantly extended
15 half-life of 84 ± 4.6 h. The variant with the weakest affinity for which there was no difference in pharmacokinetic profile from gL4gH5 was gL5gH5 (**Fig. 5**). gL5gH5 contained a single mutation in the light chain, W30A, and its affinity was 453 nM. This affinity was 368-fold weaker than that of gL4gH5 (1.23 nM) but its half-life (96.7 ± 20.4 h) was equivalent to that of gL4gH5. A change in the pharmacokinetic profile was observed for gL4gH37. It has a
20 single mutation in the heavy chain, F58E, and its affinity was 955 nM. This affinity was 776-fold lower than gL4gH5 but the half-life still extended to 61 ± 16.8 h. gL5gH47 contained one mutation in the light chain, W30A, and one mutation in the heavy chain, T100aS, and had an affinity of 52 μ M, as measured by steady state SPR. This affinity was 42,276-fold weaker than that of gL4gH5, and yet the pharmacokinetic profile did not differ dramatically
25 from gL4gH37 and the half-life increased to 26.3 ± 3.1 h.

The mutants were designed and selected on the basis of affinity for HSA but the pharmacokinetic model was murine. Therefore, to confirm that the affinities of the mutants for HSA reflected their affinities for albumin in a mouse, SPR was repeated (**Table 5**). The
30 affinities of gL4gH5 and gL5gH5 were 1.8 and 254 nM for HSA, and similarly 2.2 and 316 nM for MSA. These data were in line with the previously determined affinities of gL4gH5 and gL5gH5 for HSA of 1.23 and 453 nM, respectively.

Using a solution of the mass action quadratic equation, we can estimate the percentage of free
35 Fab in the blood for each of the variants.³¹ If we assume the concentration of MSA (65.9 kDa) is 44 g/L and the volume of the blood of a 20 g mouse is 2 ml, then for a dose at 10 mg/kg, the concentration of CA645 Fab (47.9 kDa) will be 2087 nM. **Figure 6** shows a graph of the percentage of free Fab versus affinity for albumin in the range 1- 10^6 nM. With an

affinity for MSA of 2.2 nM, just 0.0003 % of gL4gH5 Fab is predicted to be unbound in blood. The affinity for MSA of gL5gH5 Fab is 316 nM. It has a pharmacokinetic profile and half-life that matches that of gL4gH5, and is calculated to have a similarly low level of free Fab at 0.05 %. We were unable to measure the affinities of gL4gH37 and gL5gH47 Fabs for 5 MSA. However, as the affinities of gL4gH5 and gL5gH5 were both 1.2-fold weaker for MSA than for HSA (**Table 5**), it is reasonable to predict that the affinities of gL4gH37 and gL5gH47 will be proportionately 1.2-fold weaker. Therefore, with predicted affinities for MSA of 1146 nM and 62.4 μ M, it is calculated that 0.17 % of gL4gH37 and 8.57 % of gL5gH47, respectively, are potentially free in blood.

Table 1 Binding of various antibodies generated

mAb CA no.	FMAT			SPR			Humanized IgG	
	B cell sup		Fab	Rabbit		HSA		
	HSA	compounds		RSA	K_D	K_D		
645	272	220	114	0.31	2.6	0.82	2.9	
646	2310	964	484	0.14	1.6	0.57	1.7	
647	1213	520	69	0.60	36.0	1.30	26	
648	1048	465	72	0.33	12.0	0.13	23	
649	1338	534	142	0.54	13.0	0.32	17	
							44	
							188	
							161	

Table 2 Binding Kinetics of CA645 gL4Gh5 Fab to HAS, MSA, CSA, RSA and RbSA

Albumin	$k_a \times 10^4$ (1/Ms)	$k_d \times 10^{-4}$ (1/s)	$K_D \times 10^{-9}$ (M)
Human	9.0	4.1	4.6
Mouse	4.8	3.4	7.1
Rat	2.4	13	54
Cynomolgus	10	3.5	3.3
Rabbit	0.2	2.9	162
Bovine	-	-	No binding

Table 3 X-ray data

	Fab_645	Fab_645-HSA
Data collection		
Space group	P 3 ₁ 2 1	P 3 ₁ 2 1
Cell dimensions		
<i>a, b, c</i> (Å)	111.21, 111.21, 89.20	217.68, 217.68, 78.68
α, β, γ (°)	90.00, 90.00, 120.00	90.00, 90.00, 120.00
Resolution (Å)	30.0-2.68 (2.82- 2.32)*	30.0-3.58 (3.79- 3.58)*
R_{merge}	0.117(0.357)	0.157(0.612)
R_{meas}	0.120(0.365)	0.108(0.439)
$CC_{1/2}$	99.7(98.2)	99.5(78.5)
$I / \sigma I$	23.0(10.1)	7.57(1.64)
Completeness (%)	99.5(99.4)	93.9(86.1)
Redundancy	21.5(22.2)	2.4(1.9)
Refinement		
Resolution (Å)	30.00-2.68	30.00-3.6
No. reflections	389,935	110,160
$R_{\text{work}} / R_{\text{free}}$	0.2114 / 0.2513	0.2138 / 0.2523
No. atoms		
Protein	3311 (excluding H)	7870 (ex H)
Water	37	-
<i>B</i> -factors		
Protein	31.55	115.14
Water	24.24	-
R.m.s. deviations		
Bond lengths (Å)	0.007	0.010
Bond angles (°)	1.447	1.446

Table 4
mutation

SPR						Half-life (h)				
			<i>k</i> _a	<i>k</i> _d	<i>K</i> _D	M1	M2	M3	Mean	SD
CA645	Light	Heavy	$\times 10^5$	$\times 10^{-4}$	$\times 10^{-9}$					
Grafts	chain	chain	(1/Ms)	(1/s)	(M)					
gL4gH5	-	-	1.39	1.72	1.23	85	88	79	84	4.6
gL5gH5	W30A	-	1.26	571	453	120	82	88	96.7	20.4
gL4gH37	-	F58E	0.61	583	955	55	48	80	61	16.8
gL5gH47	W30A	T100aS	-	-	52μM*	27	23	29	26.3	3.1
gL5gH37	W30A	F58E	-	-	NB	0.54	0.42	0.47	0.48	0.06

Table 5

CA645 Grafts	Albumin species	k_a $\times 10^4$ (1/Ms)	k_d $\times 10^{-4}$ (1/s)	K_D $\times 10^{-9}$ (M)
gL4gH5	HSA	22	4.0	1.8
gL4gH5	MSA	31	6.8	2.2
gL5gH5	HSA	8.5	220	254
gL5gH5	MSA	1.2	38	316

Table 6

pH	KD (nM)
5.0	7.1
5.5	10.7
6.0	12.5
7.0	13.3

5 **Table 7A**

CA645 Grafts	Light chain mutation	Heavy chain mutation	k_a $\times 10^4$ (1/Ms)	k_d $\times 10^{-4}$ (1/s)	K_D $\times 10^{-9}$ (M)
gL4gH5	-	-	5.75	1.23	2.14
gL10gH5	S28A	-	13.80	1.72	1.03
gL12gH5	S28D	-	5.54	1.04	1.88
gL13gH5	S28I	-	5.76	1.08	1.88
gL14gH5	S28L	-	5.77	0.87	1.51
gL27gH5	F32Y	-	6.21	5.86	9.44
gL34gH5	S93T	-	5.58	1.90	3.41
gL35gH5	S93V	-	5.21	2.90	5.57
gL4gH43	-	G98E	5.29	3.91	7.39
gL4gH44	-	G98L	5.35	2.26	4.22
gL4gH45	-	G98V	5.38	4.44	8.25
gL4gH27	-	A53G	4.83	0.84	1.73

gL4gH28	-	A53V	4.85	5.15	10.62
gL4gH29	-	A53S	4.77	3.80	7.97
gL4gH30	-	A53T	4.38	10.2	23.17
gL4gH38	-	F58Y	4.75	5.81	12.23
gL4gH39	-	G98I	5.35	7.50	14.01
gL4gH40	-	G98T	5.56	3.56	6.40
gL4gH41	-	G98D	5.37	3.51	6.54
gL4gH42	-	G98Q	5.31	2.22	4.17
gL4gH5	-	-	5.60	1.40	2.51

Table 7B

CA645 Grafts	Light chain mutation	Heavy chain mutation	k_a $\times 10^4$ (1/Ms)	k_d $\times 10^{-4}$ (1/s)	K_D $\times 10^{-9}$ (M)
gL4gH5	-	-	5.91	1.61	2.72
gL15gH5	S31R	-	6.01	2.77	4.62
gL16gH5	S31W	-	5.53	1.69	3.06
gL17gH5	S31N	-	5.88	3.23	5.50
gL18gH5	S31I	-	5.32	8.23	15.47
gL19gH5	S31D	-	5.20	2.60	5.00
gL20gH5	S31Q	-	5.55	7.94	14.30
gL21gH5	S31E	-	5.10	3.23	6.34
gL22gH5	S31H	-	5.57	4.78	8.58
gL23gH5	S31L	-	5.49	8.14	14.82
gL24gH5	S31V	-	5.47	8.83	16.14
gL25gH5	S31F	-	5.62	2.17	3.85
gL26gH5	S31Y	-	6.01	2.48	4.13
gL4gH31	-	S54V	4.00	1.67	4.18
gL4gH32	-	S54I	3.86	1.69	4.38

gL4gH33	-	S54L	3.89	2.40	6.18
gL4gH34	-	S54Q	3.85	4.22	10.97
gL4gH35	-	S54E	2.65	3.99	15.06
gL4gH5	-	-	5.86	1.58	2.70

Table 7C

CA645 Grafts	Light chain mutation	Heavy chain mutation	k_a $\times 10^4$ (1/Ms)	k_d $\times 10^{-4}$ (1/s)	K_D $\times 10^{-9}$ (M)
gL4gH5	-	-	5.62	1.67	2.97
gL11gH5	S28N	-	5.64	2.49	4.42
gL28gH5	S67L	-	5.90	1.09	1.85
gL29gH5	S67V	-	5.77	1.03	1.78
gL30gH5	S67I	-	5.84	0.94	1.61
gL31gH5	S67T	-	5.72	1.42	2.49
gL32gH5	S67Q	-	5.86	1.43	2.44
gL33gH5	S67E	-	5.40	1.79	3.32
gL4gH46	-	V96Y	5.64	1.84	3.26
gL4gH47	-	T100aS	6.16	34.10	55.39
gL4gH5	-	-	5.57	2.11	3.80

References

1. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. *Curr Opin Biotechnol* 2011; 22: 868-876.
2. Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. *Biochim Biophys Acta* 2013; 1830: 5526-5534.
3. Peters TJr. All About Albumin: Biochemistry, Genetics, and Medical Applications 1996; San Diego, CA: Academic Press.
4. Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, Anderson CL. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. *J Exp Med* 2003; 197: 315-322.

5. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal receptor. *Proc Natl Acad Sci U S A* 1996; 93: 5512-5516.
6. Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. *J Biol Chem* 2007; 282: 12650-12660.
7. Elsadek B, Kratz F. Impact of albumin on drug delivery – New applications on the horizon. *J Control Release* 2012; 157: 4-28.
8. Sørensen AR, Stidsen CE, Ribel U, Nishimura E, Sturis J, Jonassen I, Bouman SD, Kurtzhals P, Brand CL. Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. *Diabetes Obes Metab* 2010; 12: 655-673.
9. Trüssel S, Dumelin C, Frey K, Villa A, Buller F, Neri D. New strategy for the extension of the serum half-life of antibody fragments. *Bioconjug Chem* 2009; 20: 2286-2292.
10. Dennis MS, Zhang M, Meng Y G, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. *J Biol Chem* 2002; 277: 35035-35043.
11. Nguyen A, Reyes AE 2nd, Zhang M, McDonald P, Wong WL, Damico LA, Dennis MS. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. *Protein Eng Des Sel* 2006; 9: 291-297.
12. Hopp J, Hornig N, Zettlitz KA, Schwarz A, Fuss N, Müller D, Kontermann RE. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. *Protein Eng Des Sel* 2010; 23: 827-834.
13. Andersen JT, Pehrson, R, Tolmachev V, Daba, MB, Abrahmsén L, Ekblad C. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. *J Biol Chem* 2011; 286: 5234-5241.
14. Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, Leemans CR, van Dongen GA. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. *Mol Cancer Ther* 2008; 8: 2288-2297.
15. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, Hart B, Poelmans S, Bontinck L, Hemeryck A, Jacobs S, Baumeister J, Ulrichs H. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. *Arthritis Research & Therapy* 2015.
16. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, Tomlinson IM. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. *Protein Eng Des Sel* 2008; 21: 283-288.

17. O'Connor-Semmes RL, Lin J, Hodge RJ, Andrews S, Chism J, Choudhury A, Nunez DJ. GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans-PK/PD and safety. *Clin Pharmacol Ther* 2014; 96: 704-712.
18. Flanagan RJ, Jones AL. Fab antibody fragments. *Drug Safety* 2004; 27: 1115-1133.
19. Smith BJ, Popplewell A, Athwal, D, Chapman AP, Heywood S, West SM, Carrington B, Nesbitt A, Lawson AD, Antoniw P, Eddelston A, Suitters A. Prolonged in vivo residence times of antibody fragments associated with albumin. *Bioconjug Chem* 2001; 12: 750-756.
20. Lightwood DJ, Carrington B, Henry AJ, McKnight, AJ, Crook K, Cromie K, Lawson AD. Antibody generation through B cell panning on antigen followed by in situ culture and direct RT-PCR on cells harvested en masse from antigen-positive wells. *J Immunol Methods* 2006; 316: 133-143.
21. Tickle S, Adams R, Brown D, Griffiths M, Lightwood DJ, Lawson AD. High-throughput screening for high affinity antibodies. *J Lab Auto* 2009; 14(5): 303-307.
22. Clargo AM, Hudson AR, Ndlovu W, Wootton RJ, Cremin LA, O'Dowd VL, Nowosad CR, Starkie DO, Shaw SP, Compson JE, White DP, MacKenzie B, Snowden JR, Newnham LE, Wright M, Stephens PE, Griffiths MR, Lawson AD, Lightwood DJ. The rapid generation of recombinant functional monoclonal antibodies from individual, antigen-specific bone marrow-derived plasma cells isolated using a novel fluorescence-based method. *MAbs* 2014; 6: 143-159.
23. Adair JR, Athwal DS, Emtage JS. Humanised Antibodies International Patent Publication. 1991; WO91/09967.
24. Curry S. Lessons from the crystallographic analysis of molecule binding to Human Serum Albumin. *Drug Metab Pharmacokinet* 2009; 24(4): 342-357.
25. Oganesyan V, Damschroder MM, Cook, KE, Li, Q, Gao C, Wu H, Dall'acqua WF. Structural insights into neonatal Fc receptor-based recycling mechanisms. *J Biol Chem* 2014; 289: 7812-7824.
26. Ascenzi, P. & Fasano, M. Allostery in a monomeric protein: The case of human serum albumin. *Biophys Chem* 2010; 148: 16-22.
27. Bal W, Sokolowska M, Kurowska E, Faller P. Binding of transition metal ions to albumin: Sites, affinities and rates. *Biochim Et Biophys Act* 2013; 1830 (12): 5444-5445.
28. Ghuman J, Zunzain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. Structural basis of the drug-binding specificity of human serum albumin. *J Mol Biol* 2005; 353: 38-52.
29. Curry S, Mandelkow H, Brick P, Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. *Nat Struct Biol* 1998; 5: 827-835

30. Majorek KA, Porebski PJ, Dayal A, Zimmerman MD, Jablonska K, Stewart AJ, Chruszcz M, Minor W. Structural and immunologic characterization of bovine, horse, and rabbit serum albumins. *Mol Immunol* 2012; 52: 174-182
31. Steward MW, Steensgard J. Antibody affinity: thermodynamic aspects and biological significance 1983. CRC Press.
32. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest, 1991; 5th edit Public Health Service, National Institutes of Health, Bethesda, MD.
33. Cain K, Peters S, Hailu H, Sweeney B, Stephens P, Heads J, Sarkar K, Ventom A, Page C, Dickson A. A CHO cell line engineered to express XBP1 and ERO1-L α has increased levels of transient protein expression. *Biotechnol Prog* 2013; 29: 697-706.
34. Leslie AGW. *Acta Cryst* 2006; D62: 48-57
35. Leslie AGW, Powell HR. Evolving Methods for Macromolecular Crystallography 2007; 245: 41-51; ISBN 978-1-4020-6314-5
36. Evans P. *Acta Cryst* 2006; D62: 72-82
37. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. *J Appl Cryst* 2007; 40: 658-674
38. Kabsch W. XDS. *Acta Cryst* 2010; D66: 125-132.
39. Cao H.L, Yin DC. High-resolution Crystal Structural Variance Analysis between Recombinant and Wild-type Human Serum Albumin. To be published. DOI:[10.2210/pdb4g03/pdb](https://doi.org/10.2210/pdb4g03/pdb)
40. Brünger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. Crystallography & NMR system: A new software suite for macromolecular structure determination. *Acta Crystallogr D Biol Crystallogr* 1998; 54 (Pt 5): 905-21
41. Brünger AT. Version 1.2 of the Crystallography and NMR system. *Nature Protocols* 2007; 2: 2728 - 2733
42. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* 2004; D60: 2126-32
43. Chen VB, Arendall III WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. *Acta Crystallogr D Biol Crystallogr* 2010; D66: 12-21
44. DeLano WL The PyMOL Molecular Graphics System 2002; DeLano Scientific LLC, San Carlos, CA.

Claims:

1. A binding domain comprising a VH and VL specific to a serum carrier protein wherein the binding domain is mutated by a modification selected from one or two amino acid substitutions in the light chain variable domain (VL), one or two mutations in the heavy chain variable domain (VH) and a combination thereof, and the mutated binding domain has a half-life which is higher or lower than the half-life for the unmutated binding domain, with the proviso that the mutation is other than a mutation consisting of I50A, T56A, T95A, V96A, P97A, G98A, Y99A, S100A, T100Aa, Y100Ca, I50A and T95A, I50A and G98A, I50A and Y99A, T56A and T95A, T56A and G98A, and T56A and Y99A of SEQ ID NO: 1.
2. A binding domain according to claim 1, wherein the serum carrier protein is selected from thyroxine-binding protein, transthyretin, α 1-acid glycoprotein, transferrin, fibrinogen and albumin, or a fragment of any thereof.
3. A binding domain according to claim 2, wherein the serum carrier protein is albumin, for example human serum albumin.
4. A binding domain according to claim 3, wherein the binding domain binds to domain II of albumin.
5. A binding domain according to any one of claims 1 to 4, wherein the mutation is at least one substitution in the VL.
6. A binding domain according to claim 5, wherein the mutation is substitution of one amino acid in the VL.
7. A binding domain according to claim 5, wherein the mutation is substitution of two amino acids in the VL.
8. A binding domain according to any one of claims 5 to 7, wherein a mutation is in a CDR selected from L1, L2, L3 and a combination thereof.
9. A binding domain according to claim 8, wherein the CDR is L1.
10. A binding domain according to claim 9, wherein the mutated amino acid(s) is/are independently selected from a position 26, 27, 28, 29, 30, 31, 32, 33, 34 and 35.
11. A binding domain according to claim 10, wherein the position is 30.

12. A binding domain according to claim 10 or 11, wherein the amino acid at the relevant position(s) is replaced by a hydrophobic residue, for example selected from alanine, isoleucine, phenylalanine, valine, proline, and glycine, such as alanine.
13. A binding domain according to any one of claims 5 to 11, wherein the mutations consist of modifications to the VL.
14. A binding domain according to any one of claims 1 to 12, wherein the mutation is in the VH domain.
15. A binding domain according to claim 14, wherein the mutation is substitution of one amino acid in the VH.
16. A binding domain according to claim 14, wherein the mutation is substitution of two amino acids in the VH.
17. A binding domain according to claim 15 or 16, wherein a mutation is in a CDR selected from H1, H2, H3 and combinations thereof.
18. A binding domain according to claim 17, wherein the CDR is H2 and/or H3.
19. A binding domain according to claim 18, wherein the CDR is H2.
20. A binding domain according to any one of claims 14 to 19, wherein the mutated amino acid(s) is/are independently selected from a position 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 or 65.
21. A binding domain according to claim 20, wherein the amino acid at the relevant position(s) is replaced by a hydrophobic residue, for example selected from alanine, isoleucine, phenylalanine, valine, proline, and glycine, such as alanine.
22. A binding domain according to any one of claims 18 to 21, wherein the CDR is H3.
23. A binding domain according to claim 22, wherein the mutated amino acid(s) is/are independently selected from a position 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106 or 107.
24. A binding domain according to claim 23, wherein residue 101 is mutated.
25. A binding domain according to claim 23 or 24, wherein the amino acid at the relevant position(s) is replaced by a hydrophobic residue, for example selected from alanine, isoleucine, phenylalanine, valine, proline, and glycine, such as alanine.

26. A binding domain according to any one of the preceding claims wherein the one or more amino acid substitution is a non-conservative amino acid substitution.
27. A binding domain according to claim 26, wherein the non-conserved amino acid is selection from the natural amino acids alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, tryptophan, threonine, asparagine, glutamine, glycine, proline, arginine, lysine, aspartic acid and glutamic acid.
28. A binding domain according to any one of claims 1 to 27, wherein the binding domain comprises a CDR grafted variable domain.
29. A binding domain according to claim 28, wherein the binding domain is humanised.
30. A binding domain according to claim 29, wherein the humanised binding domain comprises a human framework in the VH and/or VL.
31. A binding domain according to claim 30, wherein the VH framework is human (for example VH3, such as VH3 1-3 3-23), for example comprising 1, 2, 3, 4, 5 or 6 amino acid substitutions, such as amino acids which are donor residues.
32. A binding domain according to claim 31, wherein the VH has a sequence shown in SEQ ID NO: 2, 3, 4, 5 or 6 (particularly 5 or 6) or a variant of any one of the same with at least 95, 96, 97, 98 or 99% similarity of identity, such as a sequence shown in SEQ ID NO: 2, 3, 4, 5 or 6 (particularly 5 or 6).
33. A binding domain according to any one of claims 30 to 31, wherein the VL framework is human (for example Vκ1, such as 2-1- (1) L5), for example comprising 1, 2 or 3 amino acid substitutions, such as amino acids which are donor residues.
34. A binding domain according to any one of claims 1 to 33, wherein the VL domain comprises a sequence selected from SEQ ID NO: 6, 7, 8 and 9 or a variant of any one of the same with at least 95, 96, 97, 98 or 99% similarity or identity, such as a sequence selected from SEQ ID NO: 6, 7, 8 and 9 (in particular 8 or 9).
35. A binding domain according to claim 36, wherein the VH and VL sequences are selected from the combinations SEQ ID NO: 2 & 6, 2 & 7, 2 & 8, 2 & 9, 3 & 6, 3 & 7, 3 & 8, 3 & 9, 4 & 6, 4 & 7, 4 & 8, 4 & 9, 5 & 6, 5 & 7, 5 & 8 and 5 & 9 or a variant or variants of any of the same with at least 95, 96, 97, 98 or 99% similarity or identity.
36. A binding domain according to claim 35, wherein the VL and VH sequences are SEQ ID NO: 9 and SEQ ID NO: 3, respectively.

37. A binding domain according to claim 35, wherein the VL and VH sequences are SEQ ID NO: 8 and SEQ ID NO: 4 respectively.
38. A binding domain according to claim 35, wherein the VL and VH sequences are SEQ ID NO: 9 and SEQ ID NO: 5 respectively.
39. A binding domain according to claim 35, wherein the VL and VH sequences are SEQ ID NO: 9 and SEQ ID NO: 4 respectively.
40. An antibody molecule comprising a binding domain according to any one of claims 1 to 39.
41. A pharmaceutical composition comprising a binding domain according to any one of claims 1 to 39 or an antibody molecule according to claim 40.
42. A method of treating a patient comprising administering a therapeutically effect amount of a binding domain according to any one of claims 1 to 39, an antibody molecule according to claim 40, or a pharmaceutical composition according to claim 41.
43. A binding domain according to any one of claims 1 to 39, an antibody molecule according to claim 40, or a pharmaceutical composition according to claim 41, for use in treatment.
44. A binding domain according to any one of claims 1 to 40, an antibody molecule of claim 40 or a pharmaceutical composition according to claim 41 for use in treatment, in particular the treatment of selected from the group consisting of infections (viral, bacterial, fungal and parasitic), endotoxic shock associated with infection, arthritis such as rheumatoid arthritis, asthma such as severe asthma, chronic obstructive pulmonary disease (COPD), pelvic inflammatory disease, Alzheimer's Disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, vasculitis, surgical adhesions, stroke, Type I Diabetes, lyme disease, meningoencephalitis, autoimmune uveitis, immune mediated inflammatory disorders of the central and peripheral nervous system such as multiple sclerosis, lupus (such as systemic lupus erythematosus) and Guillain-Barr syndrome, Atopic dermatitis, autoimmune hepatitis, fibrosing alveolitis, Grave's disease, IgA nephropathy, idiopathic thrombocytopenic purpura, Meniere's disease, pemphigus, primary biliary cirrhosis, sarcoidosis, scleroderma, Wegener's granulomatosis, other autoimmune disorders, pancreatitis, trauma (surgery), graft-versus-host disease, transplant rejection, heart disease including ischaemic diseases such as myocardial infarction as well as atherosclerosis, intravascular coagulation, bone resorption, osteoporosis, osteoarthritis, periodontitis, hypochlorhydia and cancer,

including breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney, and cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof.

45. Use of a binding domain according to any one of claims 1 to 39, an antibody molecule according to claim 40, or a pharmaceutical composition according to claim 41, in the manufacture of a medicament, for example for the treatment of selected from the group consisting of infections (viral, bacterial, fungal and parasitic), endotoxic shock associated with infection, arthritis such as rheumatoid arthritis, asthma such as severe asthma, chronic obstructive pulmonary disease (COPD), pelvic inflammatory disease, Alzheimer's Disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, vasculitis, surgical adhesions, stroke, Type I Diabetes, lyme disease, meningoencephalitis, autoimmune uveitis, immune mediated inflammatory disorders of the central and peripheral nervous system such as multiple sclerosis, lupus (such as systemic lupus erythematosus) and Guillain-Barr syndrome, Atopic dermatitis, autoimmune hepatitis, fibrosing alveolitis, Grave's disease, IgA nephropathy, idiopathic thrombocytopenic purpura, Meniere's disease, pemphigus, primary biliary cirrhosis, sarcoidosis, scleroderma, Wegener's granulomatosis, other autoimmune disorders, pancreatitis, trauma (surgery), graft-versus-host disease, transplant rejection, heart disease including ischaemic diseases such as myocardial infarction as well as atherosclerosis, intravascular coagulation, bone resorption, osteoporosis, osteoarthritis, periodontitis, hypochlorhydia and cancer, including breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney, and cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof.

FIGURE 1**(a) CA645 Heavy chain sequence alignment**

	1	10	20	30	40	
CA645 VH	<u>-QSLEESGGRLVTPGTPPLTLTCTVS</u> <u>GIDLSNYAIN</u> WVRQAPGKGLE IG					**
	***	*	*	***	*	**
VH3 1-3 3-23	EVQLLESGGGLVQPGGSLRLSCAAS					WVRQAPGKGLEWVS
gH1	<u>EVQLLESGGGLVQPGGSLRLSCAVS</u> <u>GIDLSNYAIN</u>					WVRQAPGKGLE IG
gH5	<u>EVQLLESGGGLVQPGGSLRLSCAVS</u> <u>GIDLSNYAIN</u>					WVRQAPGKGLE IG
	50	60	70	80	90	
CA645 VH	<u>IIWASGTTFYATWAKG</u> <u>RFTISRPST</u> -- <u>TV</u> D <u>LEMTSLTTADTA</u> <u>TYFCAR</u>					*****
VH3 1-3 3-23	RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK					*****
gH1	<u>IIWASGTTFYATWAKG</u> <u>RFTISRDST</u> -- <u>TV</u> Y <u>LQMNSLRAEDTAVYYCAR</u>					
gH5	<u>IIWASGTTFYATWAKG</u> <u>RFTISRDNSKNT</u> V <u>LQMNSLRAEDTAVYYCAR</u>					
	100		110			
CA645 VH	<u>TVPGYSTAPYFDL</u> <u>WGPGLTVTVSS</u>					*
JH4	<u>YFDY</u> <u>WGQGTLTVSS</u>					
gH1	<u>TVPGYSTAPYFDL</u> <u>WGQGTLTVSS</u>					
gH5	<u>TVPGYSTAPYFDL</u> <u>WGQGTLTVSS</u>					

(b) CA645 Light chain sequence alignment

	1	10	20	30	40	
CA645 VL	<u>AAVLTQTPSPVSAAVGGTVTINC</u> <u>QSSPSVWSNFLS</u> WYQQKPGQPPKLLIY					**
	*****	*	*	**	*	**
Vκ1 2-1-(1) L5	DIQMTQSPSSVSASVGDRVTITC					WYQQKPGKAPKLLIY
gL1	<u>DI</u> V <u>MTQSPSSVSASVGDRVTITC</u> <u>QSSPSVWSNFLS</u>					WYQQKPGKAPKLLIY
gL4	<u>DI</u> Q <u>MTQSPSSVSASVGDRVTITC</u> <u>QSSPSVWSNFLS</u>					WYQQKPGKAPKLLIY
	50	60	70	80	90	
CA645 VL	<u>EASKLTS</u> <u>GVPSRF</u> K <u>GSGSGTQFTLTISDVQCGDAATYYC</u> <u>GGYSSISD</u>					*****
Vκ1 2-1-(1) L5	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC					
gL1	<u>EASKLTS</u> <u>GVPSRF</u> K <u>GSGSGTDFTLTISSLQPEDFATYYC</u> <u>GGYSSISD</u>					
gL4	<u>EASKLTS</u> <u>GVPSRF</u> K <u>GSGSGTDFTLTISSLQPEDFATYYC</u> <u>GGYSSISD</u>					
	100					
CA645 VL	<u>TTFGGGTKVVVK</u>					**
Jκ4	<u>LT</u> T <u>FGGGTKVEIK</u>					
gL1	<u>TTFGGGTKVEIK</u>					
gL4	<u>TTFGGGTKVEIK</u>					

Figure 2





Figure 3





Figure 4

Figure 5**Figure 6**

% free Fab




Figure 7

SEQ ID NO: 1 CA645 VH

QSLEESGGRLVTPGTPLTLCTVSGIDLSNYAINWVRQAPGKGLEWIGIIWASGTTFYATWAKG
RFTISRPSTTVDLEMTSLTTADTATYFCARTVPGYSTAPYFDLWGPGLTVSS

SEQ ID NO: 2 CA645 VH gH1

EVQLLESGGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGKGLEWIGIIWASGTTFYATWAKG
RFTISRDSTTVYLOMNSLRAEDTAVYYCARTVPGYSTAPYFDLWQGTLTVSS

SEQ ID NO: 3 CA645 VH gH5

EVQLLESGGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGKGLEWIGIIWASGTTFYATWAKG
RFTISRDNSKNTTVYLOMNSLRAEDTAVYYCARTVPGYSTAPYFDLWQGTLTVSS

SEQ ID NO: 4 CA645 VH gH37

EVQLLESGGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGKGLEWIGIIWASGTTAYATWAKGRFTI
SRDNSKNTTVYLOMNSLRAEDTAVYYCARTVPGYSTAPYFDLWQGTLTVSS

SEQ ID NO: 5 CA645 VH gH47

EVQLLESGGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGKGLEWIGIIWASGTTFYATWAKG
RFTISRDNSKNTTVYLOMNSLRAEDTAVYYCARTVPGYSAPYFDLWQGTLTVSS

SEQ ID NO: 6 CA645 VL

AAVLQTSPSPVSAAVGGTVTINCQSSPSVWSNFLSWYQQKPGQPPKLLIYEASKLTS
GVPSRFKGSSGTQFTLTISDVQCGDAATYYCGGGYSSISDTTFGGGTKVVVK

SEQ ID NO: 7 CA645 VL gL1

DIVMTQSPSSVSASVGDRVTITCQSSPSVWSNFLSWYQQKPGKAPKLLIYEASKLTS
GVPSRFKGSSGSTDFTLTISLQPEDFATYYCGGGYSSISDTTFGGGTKVEIK

SEQ ID NO: 8 CA645 VL gL4

DIQMTQSPSSVSASVGDRVTITCQSSPSVWSNFLSWYQQKPGKAPKLLIYEASKLTS
GVPSRFSSGSGTDFTLTISLQPEDFATYYCGGGYSSISDTTFGGGTKVEIK

Figure 7 continued

SEQ ID NO: 9 CA645 VL gL5

DIQMTQSPSSVSASVGDRVATIC QSSPSVASNFLS WYQQKPGKAPKLLIY EASKLTS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC GGYSSISD TTFGGGTKVEIK

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/060266

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K16/18
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, Sequence Search, EMBASE, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009/040562 A1 (UCB PHARMA SA [BE]; HUMPHREYS DAVID PAUL [GB]; DAVE EMMA [GB]) 2 April 2009 (2009-04-02) pages 1-3,7,16, 26; claims 1-24 ----- A WO 2015/006337 A2 (NANJINGJINSIRUI SCIENCE & TECHNOLOGY BIOLOGY CORP [CN]; GENSCRIPT CORP) 15 January 2015 (2015-01-15) paragraphs [0003] - [0007] ----- -/-	1,2, 5-31,33, 40-45
A		1,2, 5-31,33, 40-45

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 July 2017	13/09/2017
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Behrens, Joyce

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/060266

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>LUCY J HOLT ET AL: "Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs", PROTEIN ENGINEERING, DESIGN AND SELEC, OXFORD JOURNAL, LONDON, GB, vol. 21, 1 January 2008 (2008-01-01), pages 283-288, XP007911765, ISSN: 1741-0126, DOI: 10.1093/PROTEIN/GZM067 [retrieved on 2008-04-02]</p> <p>abstract</p> <p>page 285, column 1</p> <p>-----</p>	1,2, 5-31,33, 40-45
A	<p>ROLAND E KONTERMANN ED - JIN YONG-SU ET AL: "Strategies for extended serum half-life of protein therapeutics", CURRENT OPINION IN BIOTECHNOLOGY, vol. 22, no. 6, 20 August 2011 (2011-08-20), pages 868-876, XP028397475, ISSN: 0958-1669, DOI: 10.1016/J.COPBIO.2011.06.012 [retrieved on 2011-07-29]</p> <p>the whole document</p> <p>-----</p>	1,2, 5-31,33, 40-45
A	<p>TICKLE S ET AL: "High-Throughput Screening for High Affinity Antibodies", JOURNAL OF THE ASSOCIATION FOR LABORATORY AUTOMATION, ELSEVIER, vol. 14, no. 5, 1 October 2009 (2009-10-01), pages 303-307, XP026565094, ISSN: 1535-5535, DOI: 10.1016/J.JALA.2009.05.004 [retrieved on 2009-09-03]</p> <p>the whole document</p> <p>-----</p>	1,2, 5-31,33, 40-45

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2017/060266

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1, 2, 5-31, 33, 40-45(all partially)

Remark on Protest

The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 2, 5-31, 33, 40-45(all partially)

A binding domain comprising a VH and VL specific to a serum carrier protein, wherein the serum carrier protein is thyroxine-binding protein or a fragment of thereof.

2. claims: 1, 2, 5-31, 33, 40-45(all partially)

A binding domain comprising a VH and VL specific to a serum carrier protein, wherein the serum carrier protein is transthyretin or a fragment of thereof.

3. claims: 1, 2, 5-31, 33, 40-45(all partially)

A binding domain comprising a VH and VL specific to a serum carrier protein, wherein the serum carrier protein is alpha 1-acid glycoprotein or a fragment of thereof.

4. claims: 1, 2, 5-31, 33, 40-45(all partially)

A binding domain comprising a VH and VL specific to a serum carrier protein, wherein the serum carrier protein is transferrin or a fragment of thereof.

5. claims: 1, 2, 5-31, 33, 40-45(all partially)

A binding domain comprising a VH and VL specific to a serum carrier protein, wherein the serum carrier protein is fibrinogen or a fragment of thereof.

6. claims: 3, 4, 32, 34-39(completely); 1, 2, 5-31, 33, 40-45(partially)

A binding domain comprising a VH and VL specific to a serum carrier protein, wherein the serum carrier protein is albumin or a fragment of thereof.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2017/060266
--

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 2009040562	A1	02-04-2009	CA 2700714 A1 CN 101842387 A CN 104004088 A EP 2195341 A1 EP 2535349 A1 EP 2535350 A1 EP 2535351 A2 ES 2622460 T3 JP 5592792 B2 JP 6106640 B2 JP 2010539921 A JP 2015002744 A US 2010239582 A1 US 2014194596 A1 US 2016311930 A1 WO 2009040562 A1	02-04-2009 22-09-2010 27-08-2014 16-06-2010 19-12-2012 19-12-2012 19-12-2012 06-07-2017 17-09-2014 05-04-2017 24-12-2010 08-01-2015 23-09-2010 10-07-2014 27-10-2016 02-04-2009
WO 2015006337	A2	15-01-2015	CN 105555310 A EP 3019192 A2 JP 2016523970 A US 2016200830 A1 WO 2015006337 A2	04-05-2016 18-05-2016 12-08-2016 14-07-2016 15-01-2015